Richard E Sutton
Overview
Explore the profile of Richard E Sutton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yukselten Y, Wishah H, Li J, Sutton R
Virology
. 2024 Dec;
603:110375.
PMID: 39729963
CCR5, a co-receptor critical for R5-tropic HIV entry into host cells, remains a key target for therapeutic interventions. HIV utilizes CCR5, expressed on T cells and macrophages, to facilitate viral...
2.
Nuwagaba J, Li J, Ngo B, Sutton R
Virology
. 2024 Dec;
603:110362.
PMID: 39705895
Significant advances in treatment have turned HIV-1 into a manageable chronic condition. This has been achieved due to highly active antiretroviral therapy (HAART), involving a combination regimen of medications, including...
3.
Yukselten Y, Akang E, Wang L, Su P, Sutton R
Virology
. 2024 Dec;
603:110341.
PMID: 39642611
HIV is still a pandemic; antiretroviral therapeutics for preventing and treating HIV infection continue to present significant challenges. The demand for new drugs and effective treatments remains ongoing. Here, we...
4.
Wang L, Yukselten Y, Nuwagaba J, Sutton R
Sci Adv
. 2024 Mar;
10(12):eadl0368.
PMID: 38507500
CCR5 serves as R5-tropic HIV co-receptor. Knocking out CCR5 in HIV patients, which has occurred <10 times, is believed important for cure. JAK/STAT inhibitors tofacitinib and ruxolitinib inhibit CCR5 expression...
5.
Slotkin R, Kyriakides T, Kundu A, Stack G, Sutton R, Gupta S
PLoS One
. 2023 Aug;
18(8):e0289713.
PMID: 37643190
Introduction: The objective of this study was to describe the correlation between the commercially available assay for anti-S1/RBD IgG and protective serum neutralizing antibodies (nAb) against SARS-CoV-2 in an adult...
6.
Hansen T, Baris J, Zhao M, Sutton R
Virology
. 2022 Sep;
576:30-41.
PMID: 36137490
Rev is an essential regulatory protein of Human Immunodeficiency Virus type 1 (HIV) that is found in the nucleus of infected cells. Rev multimerizes on the Rev-response element (RRE) of...
7.
Ssenyange G, Kerfoot M, Zhao M, Farhadian S, Chen S, Peng L, et al.
Cell Rep Methods
. 2022 Jun;
2(7):100252.
PMID: 35757815
Efficient quantitative assays for measurement of viral replication and infectivity are indispensable for future endeavors to develop prophylactic or therapeutic antiviral drugs or vaccines against SARS-CoV-2. We developed a SARS-CoV-2...
8.
Zhao M, Slotkin R, Sheth A, Pischel L, Kyriakides T, Emu B, et al.
Clin Infect Dis
. 2022 May;
76(3):e391-e399.
PMID: 35639598
Background: We studied whether comorbid conditions affect strength and duration of immune responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccination in a US-based, adult population. Methods:...
9.
Zhao M, Slotkin R, Sheth A, Pischel L, Kyriakides T, Emu B, et al.
medRxiv
. 2022 Apr;
PMID: 35411347
Background: We studied whether comorbid conditions impact strength and duration of immune responses after SARS-CoV-2 mRNA vaccination in a US-based, adult population. Methods: Sera (pre-and-post-BNT162b2 vaccination) were tested serially up...
10.
Shytaj I, Fares M, Gallucci L, Lucic B, Tolba M, Zimmermann L, et al.
mBio
. 2022 Mar;
13(2):e0370521.
PMID: 35229634
Combinations of direct-acting antivirals are needed to minimize drug resistance mutations and stably suppress replication of RNA viruses. Currently, there are limited therapeutic options against the severe acute respiratory syndrome...